DAVID QUARLES: Open Payments
NPI 1235436577 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,049 in 41 payments from 14 companies in 2025. Trend: 2023 $533 · 2024 $2,713 · 2025 $1,049
Food & beverage: $1,049
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 11 | $356 |
| Ipsen Biopharmaceuticals, Inc | 6 | $179 |
| ABBVIE INC. | 4 | $151 |
| Phathom Pharmaceuticals, Inc. | 9 | $102 |
| Fujifilm Healthcare Americas Corporation | 1 | $47 |
| Novo Nordisk Inc | 2 | $34 |
| Ardelyx, Inc. | 1 | $32 |
| QOL Medical, LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
Products named: REZDIFFRA, IQIRVO, RINVOQ, VOQUEZNA, UTASWAKO AFP-L3, DUPIXENT, Saxenda, IBSRELA.
Industry payments across MS — which companies pay providers there.
